Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Aurora Cannabis

1 Stock I’d Buy Today, 1 I Wouldn’t Touch

Good investing isn’t just about what you buy but also what you avoid.

Barchart

Aurora Cannabis Is Spiking. Barchart Options Data Tells Us ACB Stock Could Be Headed Here Next.

Aurora Cannabis stock soars on President Donald Trump’s public endorsement of CBD as a viable alternative to prescription drugs. But investors are still recommended caution in buying ACB shares here.

Barchart

Aurora Cannabis Stock Analysis: Key Levels And Trading Opportunities

Aurora Cannabis (NASDAQ: ACB) stock finds support at $4.16 amid Fibonacci analysis and bullish divergence. Learn key levels for traders.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

1 Cannabis Stock I Would Buy, and One I Would Avoid

The cannabis industry is rapidly growing, but will Canadian players be able to keep up?

Barchart

2 Cannabis Stocks I Would Flat-Out Avoid In 2024, and One I Would Buy

The cannabis industry is expanding rapidly, but only a few cannabis companies can be winners.

Barchart

Aurora Cannabis (ACB) vs. Merck (MRK): Which Pharma Stock Holds Greater Potential for Investors?

The pharmaceutical industry is poised for robust growth owing to technological advancements and growing healthcare needs. Given this backdrop, let’s analyze Aurora Cannabis (ACB) and Merck & Co. (MRK) to determine which of the two stocks holds greater potential for investors. Read on….

StockNews.com

Aurora Rolls Out An Extensive Line Of Medical & Recreational Cannabis Products

Aurora Cannabis (NASDAQ: ACB) (TSX:ACB) launched a new fall lineup of cannabis products. Drift:

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Aurora Shares Plunge On Q4 Earnings Report But This Analyst Sees Better Days Ahead, Here's Why

Aurora Cannabis Inc. (NASDAQ: ACB) reported its financial and operational results for the fourth quarter and fiscal year ending June 30, 2022

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2022

Upgrades For Berkshire Hathaway Inc (NYSE:BRK), Edward Jones upgraded the previous rating of Hold to Buy. Berkshire Hathaway earned $6312.49 in the second quarter, compared to $4399.91 in the year-ago quarter.

Benzinga

Akanda Partners With Berner's Cookies To Bring The Cannabis Brand And Its High THC Strains To Portugal

International medical cannabis platform company Akanda Corp. (NASDAQ: AKAN) signed an exclusive license agreement with international cannabis lifestyle brand Cookies.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 24, 2022

Upgrades

Benzinga

Read Why Cantor Upgraded Aurora Cannabis Stock

Cantor Fitzgerald has upgraded Aurora Cannabis Inc (NASDAQ: ACB) to Overweight from Neutral

Benzinga

Aurora Cannabis Announces More Layoffs, Here's Why

Aurora Cannabis Inc. (NASDAQ: ACB) continues to trim its workforce as it seeks to achieve profitability.

Benzinga

Bearish Sentiment Across The Cannabis Space - Check Full Movers For June 14, 2022

GAINERS: Aurora Cannabis (NASDAQ:ACB) shares closed up 5.65% at $1.31

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

Is Aurora Cannabis a Buy Under $2?

With its stock currently trading at less than $2, Aurora Cannabis (ACB) has strengthened its portfolio and made considerable progress in the worldwide medicinal cannabis market. However, given that the company is struggling to generate revenue growth in the consumer cannabis segment, is it worth buying the stock now? Read…

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 6, 2022

Upgrades

Benzinga

Aurora Cannabis Repurchases $20M Of Convertible Notes

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX:ACB), has repurchased an aggregate of approximately CA$25.3 million ($20 million) principal amount of its convertible senior notes at a total cost, including accrued interest, of CA$24.3 million ($19.2 million) in cash.

Benzinga

Aurora Cannabis Closes $172.5M Bought Deal Financing, Here Are The Details

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX:ACB) closed bought deal offering of units of the company for gross proceeds of approximately $172.5 million. The company sold approximately 70.4 million units at a price of $2.45 per unit, including approximately 9.2 million units sold pursuant to the

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Aurora Cannabis Upsizes Bought Deal Financing

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX:ACB), has amended the terms of its previously announced bought deal financing.

Benzinga

Why Aurora Cannabis Stock Is Getting Hammered Today

Aurora Cannabis Inc. (NASDAQ: ACB) shares are trading lower after the company announced it has enetered into a bought deal financing agreement. Aurora announced today that it has amended the terms of its previously announced bought deal financing.

Benzinga

Aurora Gets EU-GMP Certification For Its Cannabis Production Facility In Germany

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) has received EU-GMP certification for its state-of-the-art medical cannabis production facility in Germany.

Benzinga

Recap: Aurora Cannabis Q3 Earnings

Aurora Cannabis (NASDAQ:ACB) reported its Q3 earnings results on Thursday, May 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Aurora Cannabis missed estimated earnings by 83.33%, reporting an EPS of $-0.33 versus an estimate of $-0.18.

Benzinga

Aurora Cannabis: Q3 Earnings Insights

Benzinga

Preview: Aurora Cannabis's Earnings

Aurora Cannabis (NASDAQ:ACB) is set to give its latest quarterly earnings report on Thursday, 2022-05-12. Here's what investors need to know before the announcement. Analysts estimate that Aurora Cannabis will report an earnings per share (EPS) of $-0.18.

Benzinga

Aurora Cannabis Completes Acquisition Of Thrive Cannabis

Aurora Cannabis Inc.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.